Genmab

	3/6 06:37 af ProInvestorNEWS	ASCO24: Tagrisso cuts progression by 84% in unresectable EGFRm lung cancer (link)
	3/6 06:34 af LP90	Godmorgen :-)
	3/6 06:31 af ProInvestorNEWS	ASCO24: GSK’s Blenrep nearly halves risk of disease progression, death in myeloma study (link)
	3/6 06:28 af JKY_VH	Ja det er da for dårligt PederT og god morgen;-)
	3/6 06:08 af ProInvestorNEWS	Genmab går videre med middel mod lungekræft - foreløbige data betegnes som opmuntrende (link)
	3/6 06:03 af PederT	Vi skal jo nok ned i dag fordi at OR ikke er 100% ;-)
	3/6 06:00 af bibob	God morgen. :-)
	3/6 05:05 af ProInvestorNEWS	Preliminary Analysis of Data Evaluating Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Demonstrates 95% Overall Re (link)
	3/6 04:53 af Helge Larsen/PI-redaktør	Godmorgen :-)
	2/6 22:29 af E L	ENDO 2024 Teprotumumab Gives Lasting Relief from Thyroid Eye Disease (link)
	2/6 22:08 af E L	ASCO 2024 – acasunlimab impresses on overall survival (link)
	2/6 20:44 af Solsen	En overraskende forbedring af effekt og reduktion af bivirkninger på sc versionen af amivantamab. Det tegner godt !
	2/6 20:23 af Solsen	Tak. Men virkelig imponerende OS.
	2/6 19:05 af lossen	AI (Gemini) fortæller mig, at ALK-positiv lungekræft er en sjælden type lungekræft, som kun udgør 3-7% af alle lungekræfttilfælde
	2/6 14:35 af Solsen	Men imponerende 5 årig overlevelse på +60 % vs -10% i kontrolgruppen.
	2/6 14:35 af Solsen	Måske ikke samme patientgruppe. Thu Guadian skriver “The participants all had ALK-positive non-small cell lung cancer”
	2/6 14:32 af Solsen	Vi må finde data et sted.
	2/6 14:31 af Solsen	Lorlatinib ser ud til at være en væsentlig konkurrent (link)
	2/6 13:13 af Sukkeralf	DoR og OS for acasunlimab ser vel ganske gode ud - og Rybrevant kører derudaf, så op burde være takten, men med Genmab ved man jo aldrig. Epco betyder nok også mere…..
	2/6 12:49 af w	spørgsmålet er vel om disse opdaterede data er bedre end dem vi så for et par uger siden, hvor der blev kvitteret med minus 5%
	2/6 11:48 af lahn1	Kursen skal op op op ?
	2/6 10:56 af Vitus	Jeg tænker den falder….det plejer den ved positive nyheder…..eller fordi de er mindre positive end forventet…
	2/6 09:53 af MagnusHB	Hvad er folks forvetninger til aktiekursen imorgen? P å baggrund af de nye dataer der er kommet ud.
	2/6 09:02 af lahn1	God morgen ! og tak for de positive links

	2/6 06:36 af E L	RYBREVANT® (amivantamab-vmjw) plus lazertinib is the only chemotherapy-free regimen showing longer progression-free survival versus osimertinib in first-line treatment of patients with high-risk EGFR-mutated non-small cell lung cancer (link)
	1/6 22:48 af GeorgeBest	Combining acasunlimab with pembrolizumab showed improved efficacy and safety when pembrolizumab was administered with a 6-week dosing regimen compared to a 3-week regimen. Interestingly, liver-related events were also less frequent with the 6-week (link) pembrolizumab dosing.
	1/6 21:21 af GeorgeBest	Thanks E L. Very positive article about 1046. No mentioning of livertox. Maybe we can regain something on Monday!
	1/6 20:06 af E L	Genmab and BioNTechs Revolutionary Bispecific Antibody Shows Promising Results (link)
	1/6 18:48 af peter12	Det ser da godt ud ? (link)
	1/6 18:29 af peter12	Holozymes patent er udløbet i EU ;-)
	1/6 15:33 af E L	Investigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in Combination with Pembrolizumab Demonstrates Meaningful Clinical Activity in Phase 2 Trial in Patients with Previously Treated Metastatic Non-small Cell Lung Cancer (mNSCLC) (link)
	1/6 14:24 af lahn1	Det er en skam så mister vi vel royalties igen til en subq version af et Genmab drug :-(
	1/6 09:24 af E L	Johnson & Johnson submits application to the European Medicines Agency seeking approval of subcutaneous formulation of RYBREVANT®▼ (amivantamab) for the treatment of patients with EGFR-mutated non-small cell lung cancer (link)
	31/5 20:24 af GeorgeBest	Today, the robust clinical development of Amivantamab for EGFR-mutant NSCLC adds a new chapter looking towards a stronger future. Soon, the Paloma-3 study will be discussed by Natasha Leighl. Honored to have been part of this significant milestone (link)
	31/5 17:04 af E L	yeah, i was joking. it is amazing what they produce though sometimes...
	31/5 16:38 af lahn1	Ha EL, ville det ikke være dejligt hvis den kunne det :D Det kan den desværre ikke svare på, men den kan bruges til at analysere tekster og komme med kvalificerede bud på baseret på hvad du har fodre den med.
	31/5 16:25 af E L	Additionally, analysts “would be keen to see detail on the tolerability, particularly the avoidance of bleeding events, which had been a concern in previous studies evaluating tisotumab vedotin in head and neck cancer,” according to the report.'
	31/5 16:25 af E L	'On June 3, researchers will be presenting Phase II data on Pfizer and Genmab’s Tivdak (tisotumab vedotin) in head and neck squamous cell carcinoma. Analysts from Leerink Partners were encouraged by the data, positing that they “could see antibody drug-conjugates (ADCs) eventually replace chemotherapy in [the] head and neck cancer treatment paradigm, particularly in the second line space,” according to a report.
	31/5 16:24 af E L	ASCO24 Preview: A Look at Some of the Cancer Meeting’s Hottest Abstracts (link)
	31/5 16:24 af StockBull	Jeg kan varmt anbefale, at enhver udtalelse fra nohope tages med et gran salt. Men det ved vi jo.
	31/5 16:16 af E L	talking about arbitration; we haven't seen volume like this in years; last time bigger was september 2020 when the arbitration started...
	31/5 16:09 af E L	i don't know what to believe anymore... at least now they know how to do an arbitration correct this time around...
	31/5 16:08 af E L	no its only month end, not Q end yet
	31/5 16:08 af Sukkeralf	Yes - but do we believe that. Jan said the same about sc dara in the b eginning
	31/5 16:07 af mobbyduck1	last day.crazy volume
	31/5 16:07 af mobbyduck1	end of the q2 EL
	31/5 16:06 af E L	no i am not sure about that, i think once there was a question on the Q&A on this if i am not mistaken after Dara and Genmab answered something like 'all other contracts are fine'? anyone remember?
	31/5 16:04 af E L	wtf I see Volume 704,391shares on Yahoo, is that correct
	31/5 16:04 af Sukkeralf	Do we know for sure if Genmab gets the same royalty for an sc version of amivantamab?
	31/5 15:45 af E L	ASCO LBA out: Subcutaneous amivantamab vs intravenous amivantamab (link) . seems like a slam dunk.